Atlanta Medicines Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.35 M
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.50 M
- Revenue Growth 20.32%
- Profit Growth -36.65%
- Ebitda 33.53%
- Net Worth 16.14%
- Total Assets 26.88%
About Atlanta Medicines
Atlanta Medicines Private Limited (AMPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 March 2010 and has a history of 14 years and 11 months. Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.35 M.
The company currently has active open charges totaling ₹0.50 M.
Pavan Gupta, Lovely Gupta, Harvir Singh, and One other member serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239UP2010PTC039897
- Company No.
039897
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Atlanta Medicines?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pavan Gupta  | Director | 17-Mar-2010 | Current |
| Lovely Gupta | Director | 17-Mar-2010 | Current |
| Harvir Singh | Director | 05-Jul-2017 | Current |
| Anuj Gupta | Director | 05-Jul-2017 | Current |
Financial Performance of Atlanta Medicines.
Atlanta Medicines Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.32% increase. The company also saw a substantial fall in profitability, with a 36.65% decrease in profit. The company's net worth Soared by an impressive increase of 16.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Atlanta Medicines?
In 2022, Atlanta Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jan 2022 | Hdfc Bank Limited | ₹0.50 M | Open |
How Many Employees Work at Atlanta Medicines?
Unlock and access historical data on people associated with Atlanta Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Atlanta Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Atlanta Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.